<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-130814" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Understanding and Application of CDC Immunization Guidelines</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Balasundaram</surname>
            <given-names>Palanikumar</given-names>
          </name>
          <aff>University of Illinois College Medicine of Rockford, &#x00026; Javon Bea Hospital, Mercy Health System, IL</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sakr</surname>
            <given-names>Mohamed</given-names>
          </name>
          <aff>Brookdale Hospital Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Palanikumar Balasundaram declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohamed Sakr declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-130814.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Immunization is the most effective and safe public health intervention in reducing the incidence, prevalence, morbidity, and mortality of various infectious diseases. CDC (Center for Disease Control) issues annual updates in immunization schedules. The 2020 immunization schedule includes several updates and additions. This activity reviews the understanding and application of CDC Immunization guidelines in management by the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the Advisory Committee on Immunization Practices' recommendation and CDC immunization schedule.</p></list-item><list-item><p>Summarize 2020 CDC immunization schedule updates.</p></list-item><list-item><p>Identify factors causing noncompliance and refusal for vaccines.</p></list-item><list-item><p>Outline how interprofessional coordination and information sharing can improve patient outcomes as pertains to the CDC immunization guidelines.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/viewarticle/130814/?utm_source=pubmed&#x00026;utm_campaign=CME&#x00026;utm_content=130814">Earn FREE continuing education credits (CME/CE) on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-130814.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Immunization is the most effective and safe public health intervention in reducing the incidence, prevalence, morbidity, and mortality of various infectious diseases.<xref ref-type="bibr" rid="article-130814.r1">[1]</xref><xref ref-type="bibr" rid="article-130814.r2">[2]</xref><xref ref-type="bibr" rid="article-130814.r3">[3]</xref>&#x000a0;Vaccination is the most cost-effective preventive service. Despite the advancement in vaccine coverage, more than 40,000 adults and 300 children&#x000a0;die every year in the USA from vaccine-preventable diseases.<xref ref-type="bibr" rid="article-130814.r4">[4]</xref></p>
      </sec>
      <sec id="article-130814.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>ACIP Recommendation and CDC Immunization Schedule</bold>
</p>
        <p>A schedule is a tool that helps to shield individuals from disease by vaccinating them when they are the most vulnerable. The ACIP (Advisory Committee on Immunization Practices) gives recommendations on immunization in the United States.<xref ref-type="bibr" rid="article-130814.r5">[5]</xref>&#x000a0;After the CDC director reviews and approves the ACIP recommendation, they are published in MMWR (Morbidity and Mortality weekly report) as the final CDC recommendations for immunization in the United States.<xref ref-type="bibr" rid="article-130814.r6">[6]</xref></p>
        <p>
<bold>Annual Updates in the CDC Immunization Schedule&#x000a0;</bold>
</p>
        <p>CDC issues annual updates in immunization schedules.<xref ref-type="bibr" rid="article-130814.r7">[7]</xref>&#x000a0;New vaccines were added in some of the annual updates, e.g., Chickenpox (1996), hepatitis A (2000), pneumococcal vaccine (2001). Few vaccines were discontinued from the schedule, e.g., Oral polio vaccine (2004). New versions of existing vaccines were added, e.g., DTaP (1997), intranasal influenza (2004). Additional recommendations were advised for already existing vaccines. The current immunization schedules for children below six years comprises vaccines that prevent 14 infectious diseases, which is a drastic achievement compared with the schedule in 1948, when immunizations against only diphtheria, tetanus, pertussis, and smallpox were available. As per the immunization schedule, a child may receive up to 24 injections in the first two years of age and up to five injections in a single visit.</p>
        <p>
<bold>2020 CDC Immunization Schedule Updates</bold>
</p>
        <p>The 2020 immunization schedule includes several updates and additions. The changes in the child immunization schedule are summarized as follows,</p>
        <list list-type="bullet">
          <list-item>
            <p>Catch-up vaccination for Haemophilus influenza is not recommended for previously unvaccinated children above five years of age without risk factors.</p>
          </list-item>
          <list-item>
            <p>The catch-up immunization for Hepatitis A vaccine is recommended for all unvaccinated individuals aged 2 to 18 years.</p>
          </list-item>
          <list-item>
            <p>CDC 2020 recommends the booster doses for Meningococcal B for persons above ten years with risk factors like asplenia, complement deficiency, and microbiologists.</p>
          </list-item>
          <list-item>
            <p>Oral Polio Vaccine (OPV) doses may be counted toward the united states vaccination requirements. The OPV administered before April 1, 2016, should be counted.</p>
          </list-item>
          <list-item>
            <p>The 5th dose of the DTaP vaccine is unnecessary if the fourth dose was given after four years of age and six months after the third dose.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If a DTaP or Tdap vaccine is given at ten years of age for other reasons, it can be included as the booster dose in the CDC schedule. If the DTaP or Tdap vaccine is given at seven to nine years of age, we should not include it as the booster dose, and Tdap should be readministered at eleven to twelve years of age.&#x000a0;</p>
          </list-item>
        </list>
        <p>The changes in the Adult immunization schedule are summarized as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The age group 19 to 21 years and 22 to 26 years are combined as 19&#x000a0;to 26 years in the 2020 CDC schedule due to the change in the recommendation of catch-up HPV vaccination for all individuals aged up to 26.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A blue color box in the 2020 CDC schedule indicates shared clinical decision-making about vaccination for human papillomavirus vaccine, pneumococcal conjugate vaccine, and meningococcal B vaccine.</p>
          </list-item>
          <list-item>
            <p>Catch-up vaccination for diphtheria or tetanus after the first dose of Tdap can be given as Tdap or Td. Tdap can be used&#x000a0;wherever only Td vaccine is indicated, e.g., tetanus prophylaxis after wound management.</p>
          </list-item>
          <list-item>
            <p>CDC 2000 schedule recommends HPV vaccine for individuals 11 to 26 years of age irrespective of gender. Catch up HPV vaccination is recommended up to the age of 26 years who are not fully vaccinated. For individuals between 27 to 45 years, shared decision-making for the HPV vaccine is recommended.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Shared clinical decision making is advised for PCV13 vaccination for healthy elderly individuals above 65 years without risk factors.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Few changes are made in Hepatitis A indications for adults. HIV infection, persons experiencing homelessness are added to the existing list. Clotting factor disorders are removed from the list.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>CDC recommends shared clinical decision for the following,&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="order">
              <list-item>
                <p>Meningococcal B vaccination for 16 to 23 years</p>
              </list-item>
              <list-item>
                <p>HPV vaccine for 27 to 45 years&#x000a0;</p>
              </list-item>
              <list-item>
                <p>PCV13 for elderly individuals more than 65 years without risk factors.</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="article-130814.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>CDC recommendations in the United States currently target 17 vaccine-preventable diseases throughout their lifetime. Ten vaccines covering 14 infectious diseases are targeted for children up to 10 years. They include diphtheria, tetanus, acellular pertussis (DTaP) vaccine, Haemophilus influenza type b vaccine, measles, mumps, and rubella vaccine (MMR), varicella vaccine, pneumococcal conjugate vaccine, inactivated poliovirus vaccine, rotavirus vaccine, hepatitis A vaccine, hepatitis B vaccine, and inactivated influenza vaccine. Four vaccines covering six infectious diseases are targeted for adolescents. They include Tetanus, Diphtheria acellular pertussis (Tdap) vaccine, meningococcal conjugate vaccine, Human Papillomavirus vaccine, and the influenza vaccine.</p>
        <p>
<bold>DTaP (Diphtheria, Tetanus, acellular Pertussis) Vaccine&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The minimum age for the DTaP vaccine is six weeks.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>As per CDC guidelines, five dose series is necessary for DTaP at 2, 4, 6, 15-18 months, and 4 -6 years.</p>
          </list-item>
          <list-item>
            <p>The fifth dose is unnecessary for catch-up immunization if the fourth dose is given at more than four years of age and at least six months after the third dose.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>DTaP is not recommended beyond seven years of age. Tdap vaccine is preferred for kids after seven years of age.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Tdap (Tetanus, diphtheria, acellular pertussis) Vaccine&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tdap vaccine is administered at age 11 to 12 years and every ten years.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Also, Tdap is recommended during each pregnancy between 27 to 36 weeks gestational.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Unvaccinated children above seven years need three doses of Tdap with four weeks interval between the first two doses, six months between the second and third dose.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Haemophilus Influenza Type B (Hib) Vaccination&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Six weeks is the minimum age for the Hib vaccine's first dose.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>4-dose series at 2, 4, 6, 12&#x02013;15 months is recommended.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>As per CDC guidelines, catch up immunization for Hib in an unvaccinated kid is done as mentioned below,</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>less than 6 month - 4 dose&#x000a0;</p>
              </list-item>
              <list-item>
                <p>7-11 month - 3 doses; second dose at least four weeks from the first dose and the third dose at 12-15 months or eight weeks after the second dose, whichever is later.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>12-14 month - 2 doses eight weeks apart&#x000a0;</p>
              </list-item>
              <list-item>
                <p>15- 59 months - 1 dose&#x000a0;</p>
              </list-item>
              <list-item>
                <p>more than 60 months without risk factors (healthy children) - no need for Hib vaccines&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Special situations&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Children undergoing elective splenectomy need one dose of Hib vaccine, preferably 14 days before the procedure, irrespective of vaccine status.</p>
              </list-item>
              <list-item>
                <p>Children who had stem cell transplant need three doses of Hib four weeks apart to be started six months after transplant irrespective of vaccine status.</p>
              </list-item>
              <list-item>
                <p>Children&#x000a0;under five years of age with risk factors for Hib infection will need a similar schedule like the catch-up schedule. The risk factors include chemotherapy, radiation treatment, asplenia, sickle cell disease, immunoglobulin deficiency, early complement deficiency, and HIV infection. Unvaccinated persons from 5 -18 years with risk factors need one dose of Hib vaccine.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Hepatitis A Vaccination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Twelve months is the minimum age for the first dose of the hepatitis A vaccine.</p>
          </list-item>
          <list-item>
            <p>2-dose series is recommended with a six months interval, usually at 12 and 18 months of age.</p>
          </list-item>
          <list-item>
            <p>Catch-up immunization</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Unvaccinated individuals should complete a 2-dose series of Hepatitis A vaccine six months apart.</p>
              </list-item>
              <list-item>
                <p>Unimmunized children who have to travel to countries with high endemic hepatitis A virus should get one dose of Hepatitis A vaccine before travel and the second dose after six months. For infants aged 6-12 months, one dose of Hep A vaccine should be given before travel and revaccination with two doses after 12 months.&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Unimmunized children who had exposure to the hepatitis A virus need one dose of Hepatitis A vaccine as post-exposure prophylaxis within ten days of exposure. For children, less than 12 months with exposure needs immunoglobulin for post-exposure prophylaxis.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Hepatitis B Vaccination&#x000a0;(HBV)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Three dose series at 0, 1 to 2, and 6 to 18 months is recommended.</p>
          </list-item>
          <list-item>
            <p>All neonates above 2 Kg should get the first dose within 24 hours. For neonates less than 2 Kg, the first dose can be given at one month or before discharge from the neonatal unit.</p>
          </list-item>
          <list-item>
            <p>If neonates' mother has positive HBsAg, give Hepatitis B vaccine and hepatitis B immune globulin within twelve hours. For infants who are less than 2 Kg, an additional vaccine dose is needed at age one month. At age 9 to 12 months, the infant should be tested for HBsAg and anti-HBs.</p>
          </list-item>
          <list-item>
            <p>If the maternal HBsAg result is unknown, give Hepatitis B vaccine to the neonate within twelve hours of birth, irrespective of birth weight. The mother's HBsAg needs to be tested immediately. For infants less than 2 Kg, give Hepatitis B vaccine and Hepatitis B immune globulin within twelve hours. If the maternal HbSAg comes positive, Hepatitis B immune globulin needs to be given to neonates more than 2 Kg, as early as possible before seven days of age.</p>
          </list-item>
          <list-item>
            <p>Catch-up vaccination: 3-dose series can be started at any age for unvaccinated persons at 0, 1 to 2, 6 months.</p>
          </list-item>
        </list>
        <p>
<bold>Human Papillomavirus Vaccination (HPV)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nine years is the minimum age for the first dose of the HPV vaccine.</p>
          </list-item>
          <list-item>
            <p>Routinely HPV vaccine is initiated at 11 to 12 years of age. For individuals with a history of sexual abuse, the first dose can be started at nine years.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>CDC recommends two-dose series (0,6 month) for age group up to 14 years, and three-dose series (0,1,6 month) for 15 years and above age group.</p>
          </list-item>
          <list-item>
            <p>The catch-up HPV vaccination is recommended for all individuals aged up to 26 years.</p>
          </list-item>
        </list>
        <p>
<bold>Influenza Vaccination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The minimum age for influenza vaccine is six months for inactivated vaccine and two years for the live vaccine.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For the age group 6 months to 8 years, two doses four weeks apart are recommended for those getting them for the first time. In subsequent years kids up to 8 years can get only one dose annually. One dose is recommended for all individuals above nine years of age.</p>
          </list-item>
          <list-item>
            <p>Individuals with egg allergies can get the influenza vaccine under medical supervision.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Measles, Mumps, and Rubella Vaccination</bold>
<bold>(MMR)</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Two doses are recommended at 12 to 15 months and 4 to 6 years.</p>
          </list-item>
          <list-item>
            <p>Twelve months is the minimum age for the first dose, and a four weeks minimum interval is needed between the first and second dose.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>MMR vaccine can be given for 6&#x000a0;to 11 months children who need to travel to countries with high endemicity for measles. However, this dose does not count toward the two-dose series.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For unvaccinated individuals, two doses four weeks apart are recommended.</p>
          </list-item>
          <list-item>
            <p>MMR vaccine can be used as postexposure prophylaxis if it is given within three days of exposure.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Poliovirus Vaccination (IPV)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Six weeks is the minimum age for the first dose of IPV.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>4-dose series is administered at ages 2, 4, 6 to18 months, and 4 to 6 years.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For unimmunized children, four-dose series is recommended. The fourth dose is unnecessary if the 3rd dose is given after four years of age. IPV is not needed after 18 years of age.</p>
          </list-item>
        </list>
        <p>
<bold>Rotavirus Vaccination&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Six weeks is the minimum age for the first dose of rotavirus.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Three dose series recommended at 2,4 and 6 months for pentavalent&#x000a0;rotavirus&#x000a0;vaccine. If the monovalent&#x000a0;rotavirus&#x000a0;vaccine is administered, two-dose series at 2 and 4 months are recommended.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The series should not be started after 15 weeks of age.</p>
          </list-item>
          <list-item>
            <p>The final dose should be administered before eight months.</p>
          </list-item>
        </list>
        <p>
<bold>Varicella Vaccination&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Twelve months is the minimum age for the first dose of varicella vaccine.</p>
          </list-item>
          <list-item>
            <p>Two doses are administered at 12 to 15 months and 4 to 6 years. The second dose may be given as early as three months after the 1st dose.</p>
          </list-item>
          <list-item>
            <p>Unimmunized children less than 12 years need two doses with three months interval. For individuals above 13 years, a four weeks interval is enough.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Meningococcal Vaccine (serogroup A,C,W,Y vaccination)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For all individuals, 2-dose series is recommended at 11 to 12 years and 16 years.</p>
          </list-item>
          <list-item>
            <p>For ages 13 to 15 years, two doses with eight weeks minimum interval. The second dose should be after 16 years.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For age 16 to 18 years, only one dose is needed.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The risk factors for meningococcal infection are asplenia, sickle cell disease, complement component deficiency, and the use of eculizumab (complement inhibitor).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The minimum age for vaccination is two months for the MenACWY-CRM vaccine and nine months for the MenACWY-D vaccine.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The menACWY-CRM vaccine is given as a 4-dose series at 2, 4, 6, and 12 -15 months. For the age group 7 to 23 months, two-dose series is recommended with a 12 weeks interval and a second dose given after 12 months of age. For kids aged more than 24 months, two-dose series is recommended with an eight weeks interval.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The menACWY-D vaccine is given as a two-dose series with 12 weeks intervals for 9 to 23 months age group and eight weeks for more than 24 months age group. For kids with sickle cell disease, the MenACWY-D vaccine is administered after 24 months at least four weeks after completion of the PCV13 series.</p>
          </list-item>
          <list-item>
            <p>For individuals traveling to countries with an endemic meningococcal disease like Africa or during Hajj,&#x000a0;the MenACWY-CRM vaccine or MenACWY-D vaccine is recommended with age-specific series, as explained before.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Unvaccinated first-year college students who live in residential housing or military recruits should get one dose of MenACWY-CRM vaccine or&#x000a0;MenACWY-D vaccine.</p>
          </list-item>
        </list>
        <p>
<bold>Meningococcal Serogroup B Vaccination&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The first dose's minimum age is ten years for MenB-4C and MenB-FHbp vaccines.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Routine immunization is not necessary for all individuals. Adolescents of age 16 to 23 years without any risk factors can get vaccines based on shared clinical decision-making.</p>
          </list-item>
          <list-item>
            <p>The risk factors for meningococcal B infection are asplenia, sickle cell disease, complement component deficiency, and the use of eculizumab (complement inhibitor).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The MenB-4C vaccine is given as a 2-dose series at least one month apart.&#x000a0;The MenB-FHbp vaccine is given as a three-dose series at 0, 1 to 2, and five months.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>MenB-4C and MenB-FHbp vaccines are not interchangeable; the same product should be used for all doses in a series.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Pneumococcal Vaccination&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The minimum age is six weeks for pneumococcal conjugate vaccine-13 valent (PCV13) and two years for pneumococcal polysaccharide vaccine 23 valent (PPSV23).</p>
          </list-item>
          <list-item>
            <p>For routine immunization, the conjugate vaccine (PCV13) is used. 4-dose series is recommended at 2, 4, 6, and 12 to 15 months.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For age groups, 7 to 23 months, two-dose series is recommended with a 12 weeks interval and a second dose given after 12 months. For unimmunized healthy children aged 2 to 5 years, one dose is recommended.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>PCV13 is not routinely recommended for healthy children above five years of age.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If PCV13 and PPSV23 need to be given, PCV13 is administered first. They should not be given together on the same day.</p>
          </list-item>
          <list-item>
            <p>For high-risk children of age group 2 to 5 years, two-dose series of PCV13 with eight weeks interval followed by one dose of PPSV23 at least eight weeks after the last PCV13 dose.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>For the 6-18 years age group, vaccine series is decided as per the underlying risk factors.&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="order">
              <list-item>
                <p>Individuals with chronic cyanotic congenital heart disease, chronic liver disease, chronic asthma on high-dose steroids, and diabetes mellitus need one dose of PPSV23. They do not need a PCV13.</p>
              </list-item>
              <list-item>
                <p>Individuals with a cerebrospinal fluid leak or cochlear implant need one dose of PCV13 followed by one dose of PPSV23 after eight weeks.</p>
              </list-item>
              <list-item>
                <p>Individuals with Sickle cell disease, asplenia, immunodeficiency, HIV infection, chronic renal failure, nephrotic syndromes, leukemias, lymphomas, Hodgkin disease need one dose of PCV13 followed by two doses of PPSV23. The first dose of PPSV23 is administered eight weeks after PCV13, and the second dose is administered at least five years after dose 1 of PPSV23.</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="article-130814.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>
<bold>Vaccine Coverage&#x000a0;</bold>
</p>
        <p>As per the 2020 CDC report, the USA's vaccination rate in 2019 was approximately 95% for MMR, Varicella, and DTaP.<xref ref-type="bibr" rid="article-130814.r8">[8]</xref>&#x000a0;In the 2018-2019 school year, the measles outbreak in several states proves the need to stress school vaccination requirements for all children. Apart from parental refusal, the providers' lack of understanding about contraindications to immunization and poor patient tracking across various healthcare venues are major contributing factors for the drop in immunization coverage.<xref ref-type="bibr" rid="article-130814.r9">[9]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Vaccine Noncompliance</bold>
</p>
        <p>The immunization rate among children entering kindergarten exceeds 90 percent for all the vaccines among kids entering kindergarten. Still, we can see the emergence of vaccine-preventable diseases due to increases in vaccination delay and refusal. Measles and pertussis outbreaks happened in areas with low vaccination rates. Families refuse vaccines due to medical, religious, philosophical, or socioeconomic reasons. Clinicians have a crucial role in parental decision making for vaccination.<xref ref-type="bibr" rid="article-130814.r10">[10]</xref>&#x000a0;Patient counseling, improving access to vaccination, offering combination vaccines, and using vaccine delay alerts and reminder-recall systems incorporated in EMR help improve vaccine compliance.<xref ref-type="bibr" rid="article-130814.r11">[11]</xref><xref ref-type="bibr" rid="article-130814.r12">[12]</xref>&#x000a0;</p>
        <p>
<bold>Vaccination Recommendations During the COVID-19 Pandemic</bold>
</p>
        <p>As per CDC, the COVID pandemic has reduced the immunization rate in the 2020-2021 school year among children entering kindergarten due to decreased slots for well-visit appointments and schools not enforcing the vaccination policies because of remote learning. Separate the well-visits from sick visits at different times of the day, identifying children who have missed well-child visits, and vaccination and reminders in EMR for missed immunization can improve vaccination rate during the COVID-19 pandemic.</p>
      </sec>
      <sec id="article-130814.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=130814&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=130814">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/home/freecme/?utm_source=pubmed&#x00026;utm_campaign=FREECME&#x00026;utm_content=130814">Access free CME on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/130814/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=130814">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-130814.s7">
        <title>References</title>
        <ref id="article-130814.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bedford</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Elliman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Concerns about immunisation.</article-title>
            <source>BMJ</source>
            <year>2000</year>
            <month>Jan</month>
            <day>22</day>
            <volume>320</volume>
            <issue>7229</issue>
            <fpage>240</fpage>
            <page-range>240-3</page-range>
            <pub-id pub-id-type="pmid">10642238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plotkin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>History of vaccination.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2014</year>
            <month>Aug</month>
            <day>26</day>
            <volume>111</volume>
            <issue>34</issue>
            <fpage>12283</fpage>
            <page-range>12283-7</page-range>
            <pub-id pub-id-type="pmid">25136134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orenstein</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Simply put: Vaccination saves lives.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2017</year>
            <month>Apr</month>
            <day>18</day>
            <volume>114</volume>
            <issue>16</issue>
            <fpage>4031</fpage>
            <page-range>4031-4033</page-range>
            <pub-id pub-id-type="pmid">28396427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khabbaz</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Moseley</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Levitt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Challenges of infectious diseases in the USA.</article-title>
            <source>Lancet</source>
            <year>2014</year>
            <month>Jul</month>
            <day>05</day>
            <volume>384</volume>
            <issue>9937</issue>
            <fpage>53</fpage>
            <page-range>53-63</page-range>
            <pub-id pub-id-type="pmid">24996590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meissner</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Farizo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pickering</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Understanding FDA-Approved Labeling and CDC Recommendations for Use of Vaccines.</article-title>
            <source>Pediatrics</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>142</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30139807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poland</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Schaffner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>US Department of Health and Human Services</surname>
              </name>
            </person-group>
            <article-title>Immunization guidelines in the United States: new vaccines and new recommendations for children, adolescents, and adults.</article-title>
            <source>Vaccine</source>
            <year>2013</year>
            <month>Oct</month>
            <day>01</day>
            <volume>31</volume>
            <issue>42</issue>
            <fpage>4689</fpage>
            <page-range>4689-93</page-range>
            <pub-id pub-id-type="pmid">23583896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ventola</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 1: Childhood Vaccinations.</article-title>
            <source>P T</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>426</fpage>
            <page-range>426-36</page-range>
            <pub-id pub-id-type="pmid">27408519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seither</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McGill</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Kriss</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Mellerson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Loretan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Driver</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Knighton</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten - United States, 2019-20 School Year.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2021</year>
            <month>Jan</month>
            <day>22</day>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>75</fpage>
            <page-range>75-82</page-range>
            <pub-id pub-id-type="pmid">33476312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharts-Hopko</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Issues in pediatric immunization.</article-title>
            <source>MCN Am J Matern Child Nurs</source>
            <year>2009</year>
            <season>Mar-Apr</season>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>80</fpage>
            <page-range>80-8; quiz 89-90</page-range>
            <pub-id pub-id-type="pmid">19262260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omer</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Salmon</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Orenstein</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>deHart</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Halsey</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>May</month>
            <day>07</day>
            <volume>360</volume>
            <issue>19</issue>
            <fpage>1981</fpage>
            <page-range>1981-8</page-range>
            <pub-id pub-id-type="pmid">19420367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brelsford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Knutzen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Neher</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Safranek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Inquiries: Which interventions are effective in managing parental vaccine refusal?</article-title>
            <source>J Fam Pract</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>12</issue>
            <fpage>E12</fpage>
            <page-range>E12-E14</page-range>
            <pub-id pub-id-type="pmid">29202149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130814.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Recommended solutions to the barriers to immunization in children and adults.</article-title>
            <source>Mo Med</source>
            <year>2014</year>
            <season>Jul-Aug</season>
            <volume>111</volume>
            <issue>4</issue>
            <fpage>344</fpage>
            <page-range>344-8</page-range>
            <pub-id pub-id-type="pmid">25211867</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
